# To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)

> **NCT06687928** · PHASE1 · COMPLETED · sponsor: **Celltrion** · enrollment: 200 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** CT-P6 SC
- **BIOLOGICAL:** EU-Approved Herceptin SC

## Key facts

- **NCT ID:** NCT06687928
- **Lead sponsor:** Celltrion
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-03-26
- **Primary completion:** 2025-08-05
- **Final completion:** 2025-08-05
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06687928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06687928, "To Compare the Pharmacokinetics, Safety, and Immunogenicity of Subcutaneous CT-P6 and Herceptin in Healthy Male Subjects (Trastuzumab)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06687928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*